{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:55:08Z","timestamp":1793994908544,"version":"4.8.0"},"reference-count":74,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":244,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As new precision oncology therapies become available in the thyroid cancer (TC) treatment landscape, appropriate and timely biomarker testing is crucial for treatment selection and requires a multidisciplinary approach. Recently published European guidelines on advanced\/metastatic TC management include a special focus on biomarker testing. However, to date, there remains a need for comprehensive European guidance for standardized molecular testing strategies in TC that encompass a broad set of targetable or potentially targetable alterations, timing of testing, and patients to be tested. This expert opinion article outlines consensus testing algorithms for differentiated TC, medullary TC, and anaplastic TC from a team of endocrinologists, oncologists, molecular biologists, and pathologists to provide standardized recommendations for physicians involved in treating patients with advanced TC. In the differentiated TC algorithm, patients recommended for comprehensive testing by DNA and RNA next-generation sequencing (NGS) include those whose disease has progressed on or is resistant to radioactive iodine treatment. The medullary TC algorithm recommends RET germline testing for all patients at diagnosis. For patients exhibiting high-risk clinical or pathological features and those whose disease progresses, somatic RET testing with NGS should be discussed and conducted before considering systemic treatment. As anaplastic TC is a highly aggressive disease, molecular reflex testing for BRAF mutations is recommended for all patients at diagnosis, followed by DNA and RNA NGS for those who test BRAF negative. The article also provides consensus recommendations on the use of tumor tissue for testing and on centralization of molecular testing involving multidisciplinary tumor boards.<\/jats:p>","DOI":"10.1530\/etj-25-0024","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:26:17Z","timestamp":1750429577000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":19,"title":["Molecular predictive biomarker testing in advanced thyroid cancer \u2013 a European consensus"],"prefix":"10.1530","volume":"14","author":[{"given":"Ale\u0161","family":"Ry\u0161ka","sequence":"first","affiliation":[{"name":"The Fingerland Department of Pathology, Charles University, Faculty of Medicine 1 , ,","place":["Hradec Kralove, Czechia"]},{"name":"University Hospital 2 , ,","place":["Hradec Kralove, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital 3 , ,","place":["Barcelona, Spain"]},{"name":"Vall d\u2019Hebron Institute of Oncology (VHIO) 4 , ,","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-1392","authenticated-orcid":false,"given":"Matthias S","family":"Dettmer","sequence":"additional","affiliation":[{"name":"Klinikum Stuttgart, Institute of Pathology, Stuttgart 5 , ,","place":["Baden-W\u00fcrttemberg, Germany"]},{"name":"Institute of Tissue Medicine and Pathology, University of Bern 6 , ,","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Endocrine Unit, University Hospital of Pisa 7 , ,","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Centre at West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen 8 , ,","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-3289","authenticated-orcid":true,"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[{"name":"Service d\u2019oncologie endocrinienne, d\u00e9partement d\u2019imagerie & ENDOCAN-TUTHYREF Network, Gustave Roussy 9 , ,","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jarz\u0105b","sequence":"additional","affiliation":[{"name":"Narodowy Instytut Onkologii im. M. Curie Sklodowskiej, Gliwice Branch 10 , ,","place":["Gliwice, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":true,"given":"Laura D","family":"Locati","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia 11 , ,","place":["Pavia, Italy"]},{"name":"Istituti Clinici Scientifici Maugeri IRCCS, Medical Oncology Unit 12 , ,","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newbold","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust, Thyroid Unit 13 , ,","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tallini","sequence":"additional","affiliation":[{"name":"University of Bologna, Department of Medical and Surgical Sciences (DIMEC) Bologna 14 , ,","place":["Emilia-Romagna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Uccella","sequence":"additional","affiliation":[{"name":"Humanitas University, Milan, Italy and IRCCS Humanitas Research Hospital 15 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Harvard Medical School 16 , ,","place":["Boston, Massachusetts, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 17 , , ,","place":["Indianapolis, Indiana, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M","family":"Simon","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 17 , , ,","place":["Indianapolis, Indiana, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Camacho","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company 17 , , ,","place":["Indianapolis, Indiana, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-0982","authenticated-orcid":true,"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS and Department of Pathophysiology and Transplantation, University of Milan 18 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2026070712541801400_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2026070712541801400_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"4","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070712541801400_bib3","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"2026070712541801400_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s12020-023-03336-4","article-title":"The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma","volume":"80","author":"Basolo","year":"2023","journal-title":"Endocrine"},{"key":"2026070712541801400_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070712541801400_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12022-023-09762-4","article-title":"The unique importance of differentiation and function in endocrine neoplasia","volume":"34","author":"Asa","year":"2023","journal-title":"Endocr Pathol"},{"key":"2026070712541801400_bib7","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"key":"2026070712541801400_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1141314","article-title":"Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe","volume":"13","author":"Elisei","year":"2023","journal-title":"Front Oncol"},{"key":"2026070712541801400_bib9","article-title":"World Health Organization","volume-title":"WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours","author":"International Agency for Research on Cancer","year":"2022","edition":"5th edn"},{"key":"2026070712541801400_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1099280","article-title":"Molecular features of aggressive thyroid cancer","volume":"12","author":"Elia","year":"2022","journal-title":"Front Oncol"},{"key":"2026070712541801400_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/thy.2018.0509","article-title":"Poorly differentiated carcinoma of the thyroid gland: current status and future prospects","volume":"29","author":"Ibrahimpasic","year":"2019","journal-title":"Thyroid"},{"key":"2026070712541801400_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamaoto.2023.4323","article-title":"Molecular alterations and comprehensive clinical management of oncocytic thyroid carcinoma: a review and multidisciplinary 2023 update","volume":"150","author":"Bischoff","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026070712541801400_bib13","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3390\/curroncol31070286","article-title":"Current advances in radioactive iodine-refractory differentiated thyroid cancer","volume":"31","author":"Volpe","year":"2024","journal-title":"Curr Oncol"},{"key":"2026070712541801400_bib14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ijc.33690","article-title":"Thyroid cancer, recent advances in diagnosis and therapy","volume":"149","author":"Nabhan","year":"2021","journal-title":"Int J Cancer"},{"key":"2026070712541801400_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","article-title":"Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer","volume":"6","author":"Worden","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"2026070712541801400_bib16","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"2026070712541801400_bib17","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Translational Res"},{"key":"2026070712541801400_bib18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070712541801400_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.beem.2017.04.009","article-title":"Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer","volume":"31","author":"Hadoux","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"2026070712541801400_bib20","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1210\/clinem\/dgad061","article-title":"Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment","volume":"108","author":"Prete","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712541801400_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fendo.2020.00082","article-title":"New therapies for advanced thyroid cancer","volume":"11","author":"Laha","year":"2020","journal-title":"Front Endocrinol"},{"key":"2026070712541801400_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026070712541801400_bib23","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.18632\/oncotarget.23986","article-title":"RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"2026070712541801400_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1372553","article-title":"Advances in targeted therapy and biomarker research in thyroid cancer","volume":"15","author":"Guo","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026070712541801400_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/thy.2021.0542","article-title":"Clinical application of next-generation sequencing in advanced thyroid cancers","volume":"32","author":"Ma","year":"2022","journal-title":"Thyroid"},{"key":"2026070712541801400_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","article-title":"Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy","volume":"17","author":"Chen","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"2026070712541801400_bib28","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070712541801400_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.21037\/gs.2016.09.09","article-title":"BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence","volume":"5","author":"Czarniecka","year":"2016","journal-title":"Gland Surg"},{"key":"2026070712541801400_bib30","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.21037\/gs-20-430","article-title":"Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review","volume":"9","author":"Rashid","year":"2020","journal-title":"Gland Surg"},{"key":"2026070712541801400_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab"},{"key":"2026070712541801400_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00292-019-0600-9","article-title":"Poorly differentiated thyroid carcinoma: an underdiagnosed entity","volume":"41","author":"Dettmer","year":"2020","journal-title":"Pathologe"},{"key":"2026070712541801400_bib33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"2026070712541801400_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2026070712541801400_bib35","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.surge.2023.10.002","article-title":"Anaplastic thyroid cancer: improved understanding of what remains a deadly disease","volume":"22","author":"Cleere","year":"2024","journal-title":"Surgeon"},{"key":"2026070712541801400_bib36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-1089-7870","article-title":"Updates on the management of thyroid cancer","volume":"52","author":"Araque","year":"2020","journal-title":"Horm Metab Res"},{"key":"2026070712541801400_bib37","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr Rev"},{"key":"2026070712541801400_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"2026070712541801400_bib39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/biomedicines12040712","article-title":"Molecular pathology of thyroid tumors: essential points to comprehend regarding the latest WHO classification","volume":"12","author":"Chiba","year":"2024","journal-title":"Biomedicines"},{"key":"2026070712541801400_bib40","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"2026070712541801400_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib43","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib44","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070712541801400_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-023-03368-w","article-title":"Looking for Ret alterations in thyroid cancer: clinical relevance, methodology and timing","volume":"81","author":"Elisei","year":"2023","journal-title":"Endocrine"},{"key":"2026070712541801400_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.901004","article-title":"Predictive biomarkers in thyroid cancer","volume":"12","author":"Macerola","year":"2022","journal-title":"Front Oncol"},{"key":"2026070712541801400_bib47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2023.1379","article-title":"Diagnosis and management of tropomyosin receptor kinase fusion-positive thyroid carcinomas: a review","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026070712541801400_bib48","article-title":"Timing and ideal patient for an appropriate search for somatic RET mutation in medullary thyroid cancer","volume":"8","author":"Matrone","year":"2024","journal-title":"JCO Precision Oncol"},{"key":"2026070712541801400_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12020-023-03610-5","article-title":"Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe","volume":"83","author":"de la Fouchardiere","year":"2024","journal-title":"Endocrine"},{"key":"2026070712541801400_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.708949","article-title":"Update on targeted therapy in medullary thyroid cancer","volume":"12","author":"Okafor","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070712541801400_bib51","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/genes14071314","article-title":"Update on molecular diagnostics in thyroid pathology: a review","volume":"14","author":"Alzumaili","year":"2023","journal-title":"Genes"},{"key":"2026070712541801400_bib52","article-title":"InTERTwined: how TERT promoter mutations impact BRAFV600E-driven thyroid cancers","volume":"30","author":"Landa","year":"2023","journal-title":"Curr Opinions Endocr Metab Res"},{"key":"2026070712541801400_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070712541801400_bib54","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000346174","article-title":"2012 European Thyroid Association Guidelines for genetic testing and its clinical consequences in medullary thyroid cancer","volume":"1","author":"Elisei","year":"2013","journal-title":"Eur Thyroid J"},{"key":"2026070712541801400_bib56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070712541801400_bib57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/biomedicines11010116","article-title":"Clinicopathological profile of medullary thyroid carcinoma-could we predict aggressive behavior?","volume":"11","author":"Giusca","year":"2023","journal-title":"Biomedicines"},{"key":"2026070712541801400_bib58","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"2026070712541801400_bib59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"2026070712541801400_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/pin.13399","article-title":"Impact of the quality of resected thyroid cancer tissue sample on next-generation sequencing testing","volume":"74","author":"Hatanaka","year":"2024","journal-title":"Pathol Int"},{"key":"2026070712541801400_bib61","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-022-03343-2","article-title":"Expert opinion on NSCLC small specimen biomarker testing \u2013 part 1: tissue collection and management","volume":"481","author":"Penault-Llorca","year":"2022","journal-title":"Virchows Arch"},{"key":"2026070712541801400_bib62","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/jpm14040333","article-title":"Pathology laboratory archives: conservation quality of nucleic acids and proteins for NSCLC molecular testing","volume":"14","author":"Eccher","year":"2024","journal-title":"J Personalized Med"},{"key":"2026070712541801400_bib63","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15078","article-title":"Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists","volume":"84","author":"Kerr","year":"2024","journal-title":"Histopathology"},{"key":"2026070712541801400_bib64","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0002","article-title":"Liquid biopsies in thyroid cancers: a systematic review and meta-analysis","volume":"30","author":"Zeyghami","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070712541801400_bib65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2018.08.013","article-title":"Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer","volume":"103","author":"Allin","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026070712541801400_bib66","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Europe"},{"key":"2026070712541801400_bib67","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070712541801400_bib68","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12020-023-03610-5","article-title":"Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe","volume":"83","author":"de la Fouchardi\u00e8re","year":"2024","journal-title":"Endocrine"},{"key":"2026070712541801400_bib69","article-title":"Unlocking the potential of precision medicine in Europe \u2013 improving cancer care through broader access to quality biomarker testing","author":"European Federation of Pharmaceutical Industries and Associations (EFPIA)","year":"2021"},{"key":"2026070712541801400_bib70","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1093\/oncolo\/oyad005","article-title":"Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator","volume":"28","author":"Stenzinger","year":"2023","journal-title":"Oncologist"},{"key":"2026070712541801400_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/01945998221086203","article-title":"Establishing a multicenter network for patients with thyroid nodules and cancer: effects on referral patterns","volume":"168","author":"van Dijk","year":"2023","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026070712541801400_bib72","article-title":"Refractory thyroid tumors","author":"ENDOCAN-TUTHYREF","year":"2025"},{"key":"2026070712541801400_bib73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3390\/healthcare10091621","article-title":"Tackling thyroid cancer in Europe \u2013 the challenges and opportunities","volume":"10","author":"Horgan","year":"2022","journal-title":"Healthcare"},{"key":"2026070712541801400_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114225","article-title":"Empowering effective biomarker-driven precision oncology: a call to action","volume":"209","author":"Lawler","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/4\/ETJ-25-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/4\/ETJ-25-0024.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0024\/33261\/etj-25-0024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0024\/33261\/etj-25-0024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:22:27Z","timestamp":1783444947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/4\/e250024\/4485\/Molecular-predictive-biomarker-testing-in-advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0024","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"e250024"}}